Mineralys Therapeutics Reports Third-Quarter 2026 Net Loss of $57.3 Million
The company reported a $57.3 million net loss, compared with a $36.9 million loss a year earlier. Loss per share was $0.64 versus $0.52 in the prior-year quarter.
The company reported a $57.3 million net loss, compared with a $36.9 million loss a year earlier. Loss per share was $0.64 versus $0.52 in the prior-year quarter.